Clinical Trial

Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

Study acronym: FAPeCa
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 31, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein). The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-25.
Trial Details
NCT Number NCT06061874
Lead Sponsor Jules Bordet Institute
Conditions Cancer, Peritoneal Carcinomatosis
Enrollment 80 participants
Start Date 2023-05-30
Primary Completion 2025-06 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-31